Radiopharmaceutical startup RayzeBio has received $108 million in series C financing to support its development of targeted radiopharmaceuticals for cancer treatment.
The financing round was led by Venrock Healthcare Capital Partners, along with new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X, according to RayzeBio. In addition, all of Rayze's existing investors participated, including venBio Partners, Versant Venture, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others, the company said.
RayzeBio has now raised a total of $258 million since launching in August 2020.
